45
Participants
Start Date
June 30, 2004
Primary Completion Date
June 30, 2007
Study Completion Date
March 31, 2008
oxaliplatin, gemcitabine, bevacizumab
"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
Mount Sinai Medical Center, Miami Beach
Collaborators (2)
Sanofi-Synthelabo
INDUSTRY
Genentech, Inc.
INDUSTRY
Mt. Sinai Medical Center, Miami
OTHER